WO2015002513A2 - 호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물 - Google Patents
호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2015002513A2 WO2015002513A2 PCT/KR2014/006033 KR2014006033W WO2015002513A2 WO 2015002513 A2 WO2015002513 A2 WO 2015002513A2 KR 2014006033 W KR2014006033 W KR 2014006033W WO 2015002513 A2 WO2015002513 A2 WO 2015002513A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sirna
- double
- oligo rna
- rna structure
- ctgf
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3523—Allyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Definitions
- the present invention relates to a respiratory disease associated gene-specific siRNA and a high-efficiency double-stranded oligo RNA structure comprising the same, wherein the double-stranded oligo RNA structure is hydrophilic at both ends of the double-stranded RNA (siRNA) in order to be efficiently delivered into cells.
- the material and the hydrophobic material have a structure of the conjugated form using simple covalent bonds or linker-mediated covalent bonds, and are converted into nanoparticle form by hydrophobic interaction of the double-stranded oligo RNA structures in aqueous solution. Can be.
- SiRNA contained in the double-stranded oligo RNA structure is a specific gene associated with respiratory diseases, particularly idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease (hereinafter referred to as 'COPD'), in particular CTGF, Cyr61 or Plekho-1. It is preferred that it is siRNA.
- the present invention also relates to a method for preparing the double-stranded oligo RNA structure and a pharmaceutical composition for preventing or treating respiratory diseases, in particular idiopathic pulmonary fibrosis and COPD, comprising the double-stranded oligo RNA structure.
- RNA interference interfering RNA
- 'RNAi' interfering RNA
- RNA is converted into RNA, hereinafter called siRNA, and siRNA binds to an RNA-induced silencing complex (RISC), whereby the guide (antisense) strand recognizes and degrades the target mRNA to sequence-express the expression of the target gene.
- RISC RNA-induced silencing complex
- siRNA against the same target gene is superior to antisense oligonucleotides (ASOs) in inhibiting mRNA expression in vitro and in vivo , and the effect lasts for a long time.
- ASOs antisense oligonucleotides
- the siRNA action mechanism complementarily binds to the target mRNA and regulates the expression of the target gene in a sequence-specific manner, thus making it possible to apply targets to conventional antibody-based or small molecule drugs.
- siRNAs must be effectively delivered to target cells by improving their stability and improving cell delivery efficiency in order for siRNAs to be developed as therapeutic agents (Harnessing in vivo siRNAs). delivery for drug discovery and therapeutic development.Drug Discov Today. 2006 Jan; 11 (1-2): 67-73).
- nucleotides or backbones of siRNA are modified to have nuclease resistance or viral vectors, liposomes or nanoparticles, etc., to improve the stability in the body. Research into the use of the carrier is actively attempted.
- Non-viral delivery systems containing nanoparticles have lower cell delivery efficiency than viral delivery systems, but have high stability in vivo and target specificity. It is possible to deliver to the cell, and to improve the effect of delivering uptake and internalization of the contained RNAi oligonucleotides into cells or tissues, as well as having little cytotoxicity and immune stimulation. It is currently evaluated as a viable delivery method compared to viral delivery systems (Nonviral delivery of synthetic siRNAs in vivo . J Clin Invest. 2007 December 3; 117 (12): 3623-3632).
- a method of using a nanocarrier is used to form nanoparticles by using various polymers such as liposomes and cationic polymer complexes, and siRNA is added to these nanoparticles, that is, nanocarriers. It has a form to be supported and delivered to the cell.
- polymer nanoparticles, polymer micelles, lipoplexes, etc. are mainly used.
- lipoplexes are composed of cationic lipids. It interacts with the anionic lipids of the endosome of endosome, induces the destabilizing effect of the endosome and delivers it into cells (Proc. Natl. Acad. Sci. 15; 93 (21): 11493-8, 1996).
- siRNAs in the form of conjugated polymer compounds such as polyethylene glycol (PEG)
- PEG polyethylene glycol
- micelles composed of polymer complexes are extremely uniform in size and spontaneously formed, compared to other systems used as drug delivery vehicles, such as microspheres or nanoparticles. There is an advantage that it is easy to ensure the quality control and reproducibility of the formulation.
- siRNA conjugate conjugated to a technique for securing the stability of the siRNA and efficient cell membrane permeability has been developed (Korean Patent No. 883471).
- a hydrophilic material e.g., polyethylene glycol, PEG
- PEGylation polyethylene glycol
- a double-stranded oligo RNA structure in which hydrophilic and hydrophobic materials are coupled to oligonucleotides, especially double-stranded oligo RNA such as siRNA, has been developed.
- the structure is prepared by SAMiRNA TM (self assembled) by hydrophobic interaction of hydrophobic materials. self-assembled nanoparticles called micelle inhibitory RNA) (Korea Patent No. 1224828).
- SAMiRNA TM technology is very small in size compared to conventional delivery technologies, and can produce homogenous nanoparticles. Has the advantage that it can.
- polyethylene glycol is used as a hydrophilic substance, which is a synthetic polymer, which is often used to increase the solubility of pharmaceuticals, especially proteins, and to control pharmacokinetics.
- PEG polyethylene glycol
- one batch of polymers is made up of the sum of different numbers of monomers, resulting in a Gaussian shape with a molecular weight of polydisperse (Mw / Mn). Expresses the degree of homogeneity of the substance.
- PEG exhibits a polydispersity index of about 1.01 when the molecular weight is low (3 to 5 kDa) and a high polydispersity index of about 1.2 when the molecular weight is high (20 kDa) .
- the higher the molecular weight, the lower the homogeneity of the material. FM Veronese.Peptide and protein PEGylation: a review of problems and solutions.Biomaterials (2001) 22: 405-417). Therefore, when PEG is bound to pharmaceuticals, the polydispersity of PEG is reflected in the conjugates, which makes it difficult to verify a single substance. Therefore, the production of substances having low polydispersity index through the synthesis and purification of PEG is improved.
- the self-assembled nanoparticles are an improved form of the SAMiRNA TM technology.
- the hydrophilic material of the double-stranded RNA structure constituting SAMiRNA TM has a uniform molecular weight of 1 to 15 monomers, and, if necessary, By blocking the basic unit containing the linker and using the appropriate number as necessary, a new type of carrier having a smaller size and dramatically improved polydispersity compared to the existing SAMiRNA TM Technology was developed.
- bio-drugs act specifically on target gene sequences or protein structures, in order to evaluate efficacy and safety in non-clinical surrogate models, the species of surrogate models are the same as the bio-drugs in humans.
- substances that act as mechanisms Therefore, in order to avoid the difficulty of finding a substance containing the same mechanism as in humans, it is necessary to develop a substance that can act as the same mechanism in a human being treated and a mouse in a non-clinical surrogate model.
- Idiopathic Pulmonary Fibrosis causes severe structural changes in the lung tissue as the chronic inflammatory cells infiltrate the alveolar (lungary) walls and cause several changes that harden the lungs. It is a disease that eventually leads to pulmonary deterioration, and there are no effective treatments yet. Symptoms usually appear when diagnosed, and the median survival is only 3 to 5 years. The incidence rate is reported to be about 3-5 people per 100,000 population in foreign countries, and it is generally known that the incidence rate is higher after 50s and men are twice as high as women.
- IPF IPF
- IPF is known to continually worsen when not treated, causing more than 50% of patients to die within 3-5 years, and once the disease has progressed to complete fibrosis, no treatment can improve the treatment. If you do this, the early treatment is likely to be effective.
- Therapies currently in use include steroids, azathioprine, or cyclophosphamide, but it is difficult to see any particular effect. Trials have been attempted in animal studies and small-scale patients, but no clear effects have been demonstrated. In particular, there is no effective treatment other than lung transplantation in terminal IPF patients. Therefore, there is an urgent need to develop more efficient IPF therapeutics.
- COPD which is one of the representative lung diseases in combination with asthma, is different from asthma in that it is accompanied by irreversible airway obstruction and abnormal inflammatory reactions of the lung caused by repeated infections, inhalation of harmful particles or gases, or smoking. Respiratory diseases that are not completely reversible and have progressive airflow limitations (Pauwels et al, Am J Respir Crit Care Med , 163: 1256-1276, 2001). COPD is a disease caused by pathological changes in bronchioles and pulmonary parenchyma by airway and lung parenchymal inflammation, characterized by obstructive bronchiolitis and emphysema (pulmonary parenchymal destruction).
- Types of COPD include chronic obstructive bronchitis, chronic bronchiolitis and emphysema.
- COPD chronic obstructive bronchitis
- chronic bronchiolitis emphysema
- cytokines such as GM-CSF, TNF- ⁇ , IL-8, and MIP-2
- the airways become inflamed, the muscle walls thicken, mucus secretion increases, and bronchial obstruction appears.
- the alveoli expand and become damaged, impairing the exchange capacity of oxygen and carbon dioxide and increasing the incidence of respiratory failure.
- COPD chronic Obstructive Pulmonary Disease
- COPD chronic Obstructive Pulmonary Disease
- CTGF connective tissue growth factor
- CCN connective tissue growth factor
- CTGF in relation to fibrosis, CTGF, along with TGF- ⁇ (Transforming growth factor- ⁇ ), is known to play a role in promoting the production of ECM (extracelluar matrix) in conditions that cause sustained fibrosis or fibrosis.
- ECM extracelluar matrix
- treatment of samples or substances that inhibit the expression of CTGF or inhibit the action of ocular disorders or Muscular Dystrophy caused by abnormal expression of CTGF can be treated. No relevance has been suggested (US Patent No. 7622454, US Publication No. 20120164151).
- Cysteine-rich angiogenic inducer 61 is also an extracelluar matrix (ECM) signaling protein belonging to the CCN family, which includes cell adhesion, migration, proliferation, differentiation, It is known to regulate various cellular activities such as apoptosis.
- ECM extracelluar matrix
- Purified CYR61 promotes the attachment and spreading of endothelial cells in a similar way to fibronectin and enhances the mitogen effect of fibroblast growth factor with no mitogenic activity.
- MARIA L. KIREEVA et al. Cyr 61, a Product of a Growth Factor-Inducible Immediate-Early Gene, Promotes Cell Proliferation, Migration, and Adhesion.MOLECULAR AND CELLULAR BIOLOGY, Apr. 1996, p. 1326-1334 is also an extracelluar matrix (ECM) signaling protein belonging to the CCN family, which includes cell adhesion, migration, proliferation, differentiation, It is known to regulate various cellular activities such as apop
- Plekho1 Pulstrin homology domain-containing family O member 1
- Plekho1 is present in the plasma membrane or nucleus and is a non-enzymatic regulator of protein kinase CK2 ⁇ 1 (Casein kinase 2, alpha 1). It acts as an -enzymatic regulator and is reported to be involved in apoptosis by inhibiting AP-1 action produced by C-terminal fragments when degraded by Caspase 3 (Denis G. Bosc et al. Identification).
- CKIP-1 a Novel Pleckstrin Homology Domain-containing Protein That Interacts with Protein Kinase CK2.
- An object of the present invention is to solve the above problems, novel siRNA and double-stranded oligo RNA structure comprising the same and specific double-stranded oligonucleotide that can inhibit the expression of CTGF, Cyr61 or Plekho1 with very high efficiency It is to provide a method for producing an RNA structure.
- another object of the present invention is a pharmaceutical for preventing or treating respiratory diseases, in particular idiopathic pulmonary fibrosis and COPD, comprising the CTGF, Cyr61 or Plekho1-specific siRNA or a double-stranded oligo RNA structure comprising such siRNA as an active ingredient. It is to provide a composition.
- the first oligonucleotide having a sense strand comprising any sequence selected from the group consisting of SEQ ID NOs: 1 to 600 and 602 to 604 and an antisense strand comprising a complementary sequence thereof
- a CTGF, Cyr61 or Plekho1 specific siRNA, which is a respiratory disease associated gene consisting of 2 oligonucleotides, is provided.
- SiRNA in the present invention is a concept that includes all substances having a general RNAi (RNA interference) action, the CTGF, Cyr61 or Plekho1 specific siRNA is also included in the CTGF, Cyr61 or Plekho1 specific shRNA is that the present invention belongs It is obvious to those skilled in the art.
- RNAi RNA interference
- SEQ ID NO: 1 to 100 or 602 to 604 is a sense strand sequence of siRNA specific to CTGF ( Homo sapiens )
- SEQ ID NO: 101 to 200 is a sense strand sequence of siRNA specific to Cyr61 ( Homo sapiens )
- SEQ ID NO: 201 to 300 are sense strand sequences of siRNA specific to Plekho1 ( Homo sapiens )
- SEQ ID NOs: 301 to 400 are sense strand sequences of siRNA specific to CTGF ( Mus musculus )
- SEQ ID NOs: 401 to 500 are Cyr61 ( Mus musculus)
- SEQ ID NO: 501 to 600 is a sense strand sequence of siRNA specific to Plekho1 ( Mus musculus ).
- SiRNA according to the invention is preferably any one selected from the group consisting of SEQ ID NOs: 1 to 10, 35, 42, 59, 602, 603, 604, 301 to 303, 305 to 307, 309, 317, 323 and 329 CTGF specific siRNA comprising the sequence of the sense strand,
- Plekho1 specific siRNA comprising a sense strand of any one selected from the group consisting of SEQ ID NOs: 201 to 210, 212, 218, 221, 223, 504 to 507, 514, 515 and 522 to 525.
- CTGF comprising any one sequence selected from the group consisting of SEQ ID NO: 4, 5, 8, 9, 35, 42, 59, 601, 602, 604, 301, 303, 307 and 323 as a sense strand Specific siRNA,
- a Cry61 specific siRNA comprising a sense strand of any one sequence selected from the group consisting of SEQ ID NOs: 102, 104, 107, 108, 124, 153, 166, 187, 197, 410, 422, and 424; or
- Plekho1 specific siRNA comprising a sense strand of any one sequence selected from the group consisting of SEQ ID NOs: 206 to 209, 212, 218, 221, 223, 507, 515, and 525,
- CTGF specific siRNA comprising the sense strand of any one of the sequences according to SEQ ID NO: 42, 59, 602 or 323
- Cry61 specific siRNA comprising a sense strand of any sequence according to SEQ ID NOs: 124, 153, 187, 197 or 424
- Plekho1 specific siRNA comprising the sense strand of any one of SEQ ID NOs: 212, 218, 221, 223 or 525.
- the siRNA capable of simultaneously suppressing human and mouse CTGF, Cyr61 or Plekho1 expression is preferably a Cyr61 specific strand according to the sense strand of CTGF specific siRNA according to SEQ ID NO: 6 or 8, SEQ ID NO: 102, 104 or 105 the sense strand of the siRNA, or the sense strand of the Plekho1 specific siRNA according to SEQ ID NOs: 204, 207 or 208.
- the sense strand or antisense strand of the siRNA according to the present invention preferably comprises 19 to 31 nucleotides, and includes a sense strand comprising any one sequence selected from SEQ ID NO: 1 to SEQ ID NO: 604 and an antisense strand complementary thereto. do.
- CTGF, Cyr61 or Plekho1 specific siRNA provided in the present invention has a base sequence designed to complementarily bind to the mRNA encoding the gene, it is characterized in that it can effectively suppress the expression of the gene.
- the siRNA may include an overhang, which is a structure including one or two or more unpaired nucleotides at the 3 ′ end of the siRNA,
- the siRNA in order to improve the stability of the siRNA in vivo, it may include various modifications for imparting nuclease resistance and reducing non-specific immune responses.
- Modifications of the first or second oligonucleotides constituting the siRNA may include -CH 3 (methyl), -OCH 3 (methoxy), -NH 2, -F (-OH) at the 2 ′ carbon position of the sugar structure in one or more nucleotides.
- CTGF, Cyr61 and / or Plekho1 specific siRNAs provided in the present invention not only inhibit the expression of the gene, but also significantly inhibit the expression of the protein.
- a conjugate in which a hydrophilic material and a hydrophobic material are conjugated to both ends of an siRNA for efficient delivery and stability of respiratory disease associated genes, particularly CTGF, Cyr61 or Plekho1 specific siRNA, in vivo. do.
- siRNA conjugate in which a hydrophilic material and a hydrophobic material are bound to siRNA, self-assembled nanoparticles are formed by hydrophobic interaction of the hydrophobic material (Korean Patent Registration No. 1224828). Not only is the delivery efficiency and stability in the body extremely excellent, but also the particle size is uniform, so that the QC (Quality Control) is easy, so there is an advantage that the manufacturing process as a drug is simple.
- the double-stranded oligo RNA structure comprising CTGF, Cyr61 or Plekho1 specific siRNA according to the present invention preferably has a structure as shown in the following structural formula (1).
- A is a hydrophilic substance
- B is a hydrophobic substance
- X and Y are each independently a simple covalent bond or a linker mediated covalent bond
- R represents CTGF, Cyr61 or Plekho1 specific siRNA.
- the double-stranded oligo RNA structure comprising CTGF, Cyr61 or Plekho1 specific siRNA according to the present invention has the structure of the following structural formula (2).
- A, B, X and Y are the same as the definitions in the above formula (1), S is the sense strand of CTGF, Cyr61 or Plekho1 specific siRNA, AS is CTGF, Cyr61 or Plekho1 specific siRNA Means the antisense strand of.
- the double-stranded oligo RNA construct comprising CTGF, Cyr61 or Plekho1 specific siRNA has the structure of the following structural formula (3) or (4).
- A, B, S, AS, X and Y are the same as the definitions in the above formula (1), and 5 'and 3' are CTGF, Cyr61 or Plekho1 specific siRNA sense Means the 5 'end and the 3' end of the strand.
- One to three phosphate groups are bound to the 5 ′ end of the antisense strand of the double-stranded oligo RNA structure comprising the CTGF, Cyr61, or Plekho1 specific siRNAs in the above formulas (1) to (4). It will be apparent to those skilled in the art that shRNA may be used instead of siRNA.
- the hydrophilic materials in the above formulas (1) to (4) are preferably cationic or nonionic polymer materials having a molecular weight of 200 to 10,000, and more preferably 1,000 to 2,000 nonionic polymer materials.
- a nonionic hydrophilic polymer compound such as polyethylene glycol, polyvinylpyrrolidone, polyoxazoline, etc. as the hydrophilic polymer material, but is not necessarily limited thereto.
- the hydrophilic material (A) in the formulas (1) to (4) may be used in the form of a hydrophilic material block in the form of the following formula (5) or formula (6), which block
- n in Structural Formula (5) or Structural Formula (6) it is possible to greatly improve the problem due to polydispersity that may occur when using a general synthetic polymer material or the like.
- a ' is a hydrophilic monomer
- J is a linker for connecting between m hydrophilic monomers or m hydrophilic monomers and siRNA
- m is an integer of 1 to 15
- n is 1 to
- the repeating unit represented by (A ' m -J) or (J-A' m ) corresponds to the basic unit of the hydrophilic material block.
- the double-stranded oligo RNA construct comprising CTGF, Cyr61 or Plekho1 specific siRNA according to the present invention is represented by the following formula (7) or formula (8) It may have a structure such as.
- the hydrophilic material monomer (A ′) in the structural formula (5) and the structural formula (6) can be used without limitation as long as it meets the object of the present invention among the monomers of the nonionic hydrophilic polymer, and preferably the compound of Table 1 ( Monomers selected from 1) to compound (3), more preferably monomers of compound (1) can be used, and in compound (1) G can preferably be selected from CH 2 , O, S and NH.
- the monomer represented by the compound (1) can introduce various functional groups, and has excellent bio-compatibility such as good in vivo affinity and induces an immune response, It has the advantage of increasing the in vivo stability of the oligonucleotides contained in the structure according to the structure (7) or the structure (8) and the delivery efficiency, which is very suitable for the preparation of the structure according to the present invention.
- the hydrophilic substances in the above structural formulas (5) to (8) have a total molecular weight in the range of 1,000 to 2,000.
- hexaethylene glycol (Hexaethylene glycol) according to compound (1) in the formula (7) and formula (8) that is, when a substance of G is O and m is 6 is used hexaethylene glycol spacer ( Since the molecular weight of the spacer) is 344, it is preferable that the number of repetitions n is 3 to 5.
- the present invention is the structural formula (5) and Formula (6) in (A 'm -J) or (J-A' m) n repeating units, or hydrophilic material block (block) of the hydrophilic groups represented as needed It can be used as an appropriate number denoted by n.
- the hydrophilic material monomer A and the linker J included in each of the hydrophilic material blocks may be the same as or different from each of the hydrophilic material blocks independently.
- the first block contains the hydrophilic monomer according to compound (1)
- the second block contains the hydrophilic monomer according to compound (2)
- the third block contains Other hydrophilic material monomers may be used for every hydrophilic material block, such as a hydrophilic material monomer according to compound (3), and any hydrophilic material monomer selected from compounds (1) to (3) may be used for every hydrophilic material block.
- One hydrophilic monomer may equally be used.
- the linker that mediates the binding of the hydrophilic material monomer may be the same linker for each hydrophilic material block, or different linkers may be used for each hydrophilic material block.
- the linker (J) is preferably selected from the group consisting of PO 3 ⁇ , SO 3, and CO 2 , but is not limited thereto.
- the linker (J) may meet the object of the present invention according to the monomer of the hydrophilic material used. As long as any linker can be used, it will be apparent to those skilled in the art.
- hydrophobic substances (B) in the above formulas (1) to (4), (7) and (8) are represented by the formulas (1) to (4), (7) and (7) through hydrophobic interactions. It serves to form a nanoparticle consisting of the oligonucleotide structure according to 8).
- the hydrophobic material has a molecular weight of 250 to 1,000, a steroid derivative, a glyceride derivative, a glycerol ether, a polypropylene glycol, an unsaturated of C 12 to C 50 or Saturated hydrocarbons, diacylphosphatidylcholine, fatty acids, phospholipids, lipopolyamines, and the like may be used, but are not limited thereto, and may be used as long as they meet the object of the present invention. It is obvious to those skilled in the art that hydrophobic materials can also be used.
- the steroid derivative may be selected from the group consisting of cholesterol, cholestanol, cholic acid, cholesteryl formate, cotestanyl formate and colistanylamine, and the glyceride derivatives are mono-, di- And tri-glycerides and the like, wherein the fatty acid of glyceride is preferably C 12 to C 50 unsaturated or saturated fatty acid.
- saturated or unsaturated hydrocarbons or cholesterols are preferable in that they have an advantage of being easily bonded in the synthesis step of the oligonucleotide structure according to the present invention, and tetramethyl containing C 24 hydrocarbons, especially disulfide bonds, is preferable.
- dodosan tetradocosane
- the hydrophobic material is bound to the distal end of the hydrophilic material, and may be bonded at any position of the sense strand or the antisense strand of the siRNA.
- the hydrophilic or hydrophobic material and the CTGF, Cyr61 or Plekho1 specific siRNA in the formulas (1) to (4), (7) and (8) according to the present invention are simple covalent or linker-mediated covalent bonds. Bound by (X or Y).
- the linker that mediates the covalent bond is covalently bonded to the hydrophilic material or the hydrophobic material at the ends of the CTGF, Cyr61 or Plekho1 specific siRNA, and is not particularly limited as long as it provides a bond capable of degrading in a specific environment.
- the linker may be used any compound that binds to activate CTGF, Cyr61 or Plekho1 specific siRNA and / or hydrophilic material (or hydrophobic material) during the preparation of the double helix oligo RNA structure according to the present invention.
- the covalent bonds may be either non-degradable bonds or degradable bonds.
- the non-degradable bonds include amide bonds or phosphorylation bonds
- the degradable bonds include disulfide bonds, acid decomposable bonds, ester bonds, anhydride bonds, biodegradable bonds or enzymatic bonds, but are not limited thereto. .
- CTGF, Cyr61 or Plekho1 specific siRNAs represented by R (or S and AS) in the above formulas (1) to (4), (7) and (8) are specific to CTGF, Cyr61 or Plekho1.
- Any siRNA having a property capable of binding to each other can be used without limitation, and in the present invention, the sense strand comprising any one sequence selected from SEQ ID NOs: 1 to 600 and 602 to 604 and its complement It consists of an antisense strand comprising the host sequence.
- siRNAs included in the above formulas (1) to (4), (7) and (8) according to the present invention are preferably SEQ ID NOs: 1 to 10, 35, 42, 59, 602 to 604 or 301 CTGF specific siRNA comprising a sense strand of any one selected from the group consisting of 303, 305 to 307, 309, 317, 323 and 329,
- Plekho1 specific siRNA comprising a sense strand of any one selected from the group consisting of SEQ ID NOs: 201 to 210, 212, 218, 221, 223, 504 to 507, 514, 515 and 522 to 525.
- CTGF comprising any one sequence selected from the group consisting of SEQ ID NO: 4, 5, 8, 9, 35, 42, 59, 602, 603, 604, 301, 303, 307 and 323 as a sense strand Specific siRNA
- a Cry61 specific siRNA comprising a sense strand of any one sequence selected from the group consisting of SEQ ID NOs: 102, 104, 107, 108, 124, 153, 166, 187, 197, 410, 422, and 424; or
- Plekho1 specific siRNA comprising a sense strand of any one sequence selected from the group consisting of SEQ ID NOs: 206 to 209, 212, 218, 221, 223, 507, 515, and 525,
- CTGF specific siRNA comprising the sense strand of any one of the sequences according to SEQ ID NO: 42, 59, 602 or 323
- a Cry61 specific siRNA comprising the sense strand of any one of SEQ ID NOs: 124, 153, 187, 197 or 424, or
- Plekho1 specific siRNA comprising the sense strand of any one of SEQ ID NOs: 212, 218, 221, 223 or 525.
- CTGF specific siRNA sense strands for humans and mice according to SEQ ID NO: 6 or 8 Cyr61 specific siRNA sense strands for humans and mice according to SEQ ID NO: 102, 104 or 105, or SEQ ID NOs: 204, 207
- siRNA comprising a Plekho1 specific siRNA sense strand for humans and mice according to No. 208 wherein the siRNA having the sequence in the sense strand will simultaneously inhibit CTGF, Cyr61 or Plekho1 expression in humans and mice.
- CTGF specific siRNA sense strands for humans and mice according to SEQ ID NO: 6 Cyr61 specific siRNA sense strands for humans and mice according to SEQ ID NO: 102, or SEQ ID NO: 207
- siRNAs comprising Plekho1 specific siRNA sense strands for human and mouse accordingly.
- the present invention also provides a double-stranded oligo RNA structure comprising CTGF, Cyr61 or Plekho1 specific siRNA according to the present invention, wherein the amine group or polyhistidine group is located at the opposite terminal portion of the structure in which the hydrophilic substance is bound to the siRNA. This may be introduced further.
- the primary amine group modified at the end or the outside of the transporter forms a conjugate by electrostatic interaction with negatively charged genes while being protonated at pH in vivo, and has a buffering effect at the low pH of the endosome after inflow. It has been known that internal tertiary amines can protect the transporter from degradation of lysosomes as the endosomes escape easily (inhibition of gene transfer and expression using polymer-based hybrid materials. Polymer Sci.Technol., Vol. 23, No. 3, pp254-259),
- Histidine one of the non-essential amino acids, has imidazoling (pKa3 6.04) at residue (-R), which increases the buffering capacity in endosomes and lysosomes. It is known that histidine modifications can be used to enhance endosomal escape efficiency in non-viral gene carriers (Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte selective gene transfer in human hepatoma HepG2 cells.J. Controlled Release 118, pp 262-270).
- the amine group or polyhistidine group can be linked with a hydrophilic material or block of hydrophilic material through one or more linkers.
- an amine group or a polyhistidine group is introduced into the hydrophilic material of the double-stranded oligo RNA structure according to Structural Formula (1) of the present invention, it may have a structure as shown in Structural Formula (7).
- J 1 and J 2 is a linker
- J 1 and J 2 are independently a simple covalent bond
- J 2 is a simple covalent bond or PO 3 ⁇
- J 1 is C 6 alkyl, but is not limited thereto.
- J 2 is preferably a simple covalent bond or PO 3 ⁇
- J 1 is preferably Compound (4) in the formula (9), but is not limited thereto.
- hydrophilic material of the double-stranded oligo RNA structure according to formula (9) is a hydrophilic substance block according to formula (5) or formula (6), and when an amine group or polyhistidine group is introduced thereto, 10) or structure (11).
- the hydrophilic substance is preferably in the form bound to the 3 'end of the CTGF, Cyr61 or Plekho1 specific siRNA sense strand, in this case the formulas (9) to (11) may have the form of the following structural formulas (12) to (14).
- amine groups that can be introduced in the present invention primary to tertiary amine groups may be used, and primary amine groups are particularly preferably used.
- the introduced amine group may be present as an amine salt, for example the salt of the primary amine group may be present in the form of NH 3+ .
- polyhistidine groups which can be introduced in the present invention preferably include 3 to 10 histidines, and particularly preferably 5 to 8, most preferably 6 histidines.
- one or more cysteines may be included.
- a double-stranded oligo RNA structure comprising CTGF, Cyr61 or Plekho1 specific siRNA according to the present invention and the nanoparticles formed therefrom are provided with a targeting moiety, they efficiently promote delivery to target cells, thereby providing a relatively low concentration. It can also be delivered to target cells to exhibit high target gene expression regulating function and to prevent delivery of non-specific CTGF, Cyr61 or Plekho1 specific siRNA to other organs and cells.
- the present invention targets the ligands (L), in particular receptor-mediated endocytosis (RME), to the structures according to the above formulas (1) to (4), (7) and (8).
- L receptor-mediated endocytosis
- It provides a double-stranded oligo RNA, a structure additionally bound to a ligand having a characteristic of specifically binding to a receptor that promotes cell internalization, for example, a double-stranded oligo RNA structure according to formula (1)
- the form in which the ligand is bound to has the structure shown in the following structural formula (15).
- L is the target cell internalization through receptor-mediated endocytosis (RME)
- RME receptor-mediated endocytosis
- i is an integer from 1 to 5, preferably an integer from 1 to 3.
- the ligand in the formula (15) is preferably a target receptor specific antibody, aptamer, peptide having RME properties to enhance the internalization of the target cell specific;
- folic acid Folate, in general, folate and folic acid are used interchangeably with each other, folic acid in the present invention means folate that is active in the natural state or human body), N-acetyl galactosamine (N-acetyl Galactosamine, NAG Hexamine (hexoamine), glucose (glucose), mannose, and other chemicals such as sugar or carbohydrate (carbohydrate), such as, but is not limited thereto.
- hydrophilic material A in the formula (15) may be used in the form of a hydrophilic material block according to formula (5) and formula (6).
- the present invention provides a method for preparing a double-stranded oligo RNA structure comprising the CTGF, Cyr61 or Plekho1 specific siRNA.
- the process for preparing a double helix oligo RNA construct comprising CTGF, Cyr61 or Plekho1 specific siRNA according to the present invention is, for example,
- Solid support in the present invention is preferably Controlled Pore Glass (CPG), but is not limited thereto.
- CPG Controlled Pore Glass
- Polystyrene, silica gel, cellulose paper, or the like may be used.
- the diameter is preferably 40 to 180 ⁇ m, and preferably has a pore size of 500 to 3000 ⁇ m.
- RNA single strand comprising the RNA single strand and the complementary sequence synthesized in step (2) may be a manufacturing method characterized in that used in the form of a phosphate group bonded to the 5 'end.
- the present invention provides a method for producing a double-stranded oligo RNA structure in which ligand is additionally added to a double-stranded oligo RNA structure comprising CTGF, Cyr61 or Plekho1 specific siRNA of the present invention.
- the ligand-RNA-polymer structure and the RNA single strand of the complementary sequence are separated and purified, and then the desired ligand-RNA-polymer structure and complement by measuring the molecular weight by MALDI-TOF mass spectrometer. You can check whether the RNA is prepared.
- Ligand-double-stranded oligo RNA structures can be prepared by annealing RNA single strands of sequences complementary to the prepared ligand-RNA-polymer constructs.
- the step (4) of synthesizing the RNA single strand of the sequence complementary to the sequence of the RNA single strand synthesized in step (3) is an independent synthesis process before (1) or (1) to ( 6) may be performed during any of the steps.
- a nanoparticle comprising a double helix oligo RNA construct comprising CTGF, Cyr61 and / or Plekho1 specific siRNA.
- the double-stranded oligo RNA structure comprising CTGF, Cyr61 or Plekho1-specific siRNA is amphiphilic including both hydrophobic and hydrophilic substances, and the hydrophilic portion includes hydrogen molecules and water bonds in the body. Through interactions, they have affinity and are directed outwards, and hydrophobic materials are directed inwards through hydrophobic interactions between them, forming thermodynamically stable nanoparticles. That is, the hydrophobic material is located in the center of the nanoparticles, and the hydrophilic material is located outward of the CTGF, Cyr61 or Plekho1 specific siRNA to form a nanoparticle that protects the CTGF, Cyr61 or Plekho1 specific siRNA. .
- the nanoparticles thus formed enhance the intracellular delivery of CTGF, Cyr61 and / or Plekho1 specific siRNAs and improve siRNA efficacy.
- Nanoparticles according to the invention may be formed of a double helix oligo RNA structure containing siRNA having the same sequence, or may be composed of a double helix oligo RNA structure comprising siRNA having a different sequence
- siRNAs having different sequences in the present invention may be other target genes, for example, CTGF, Cyr61 or Plekho1 specific siRNAs, and are interpreted to include cases where the sequences have different target gene specificities.
- double-stranded oligo RNA constructs comprising other respiratory disease related gene-specific siRNAs in addition to CTGF, Cyr61 or Plekho1 specific siRNAs may be included in the nanoparticles according to the present invention.
- the present invention provides a respiratory disease, particularly idiopathic, comprising CTGF, Cyr61 and / or Plekho1 specific siRNA, a double helix oligo RNA construct comprising the same and / or nanoparticles consisting of the double helix oligo RNA construct.
- a respiratory disease particularly idiopathic, comprising CTGF, Cyr61 and / or Plekho1 specific siRNA, a double helix oligo RNA construct comprising the same and / or nanoparticles consisting of the double helix oligo RNA construct.
- a respiratory disease particularly idiopathic, comprising CTGF, Cyr61 and / or Plekho1 specific siRNA, a double helix oligo RNA construct comprising the same and / or nanoparticles consisting of the double helix oligo RNA construct.
- compositions for preventing or treating pulmonary fibrosis and COPD are provided.
- CTGF, Cyr61 or Plekho1 specific siRNA according to the present invention a double-stranded oligo RNA structure comprising the same and / or a composition comprising nanoparticles consisting of the double-stranded oligo RNA structure as an active ingredient is pulmonary artery remodeling )
- CTGF, Cyr61 or Plekho1 specific siRNA of the present invention by inhibiting airway remodeling or a composition comprising the same is effective for the prevention or treatment of respiratory diseases.
- composition for preventing or treating respiratory diseases comprising the double-stranded oligo RNA structure according to the present invention
- Double helix oligo RNA constructs comprising siRNAs;
- any one sequence selected from SEQ ID NOs 101-200 and 401-500 preferably SEQ ID NOs 101-110, 124, 153, 166, 187, 197, 409, 410, 415, 417, 418, 420, 422 , 424, 427 and 429, any one selected from the group consisting of SEQ ID NO: 102, 104, 107, 108, 124, 153, 166, 187, 197, 410, 422 and 424
- a duplex comprising a Cyr61 specific siRNA comprising a sense strand comprising a sequence of any one selected from most preferably, SEQ ID NOs: 124, 153, 187, 197 or 424 and an antisense strand comprising a sequence complementary thereto Helix oligo RNA constructs; or,
- any one sequence selected from SEQ ID NOs: 201 to 300 and 501 to 600 preferably to SEQ ID NOs: 201 to 210, 212, 218, 221, 223, 504 to 507, 514, 515 and 522 to 525
- Any one sequence selected from the group consisting of, more preferably, any one sequence selected from the group consisting of SEQ ID NOs: 206 to 209, 212, 218, 221, 223, 507, 515 and 525, most preferably SEQ ID NO: 212 A double-stranded oligo RNA construct comprising a Plekho1 specific siRNA comprising a sense strand comprising a sequence of 218, 221, 223, or 525 and an antisense strand comprising a sequence complementary thereto; May be included.
- CTGF specific siRNA comprising a sequence of SEQ ID NO: 6 or 8, preferably an antisense strand comprising a siRNA sense strand specific to both human and mouse CTGF according to SEQ ID NO: 6 and a sequence complementary thereto.
- Double-stranded oligo RNA constructs comprising a CTGF specific siRNA comprising a sequence of SEQ ID NO: 6 or 8, preferably an antisense strand comprising a siRNA sense strand specific to both human and mouse CTGF according to SEQ ID NO: 6 and a sequence complementary thereto.
- Cyr61 comprising an antisense strand comprising an siRNA sense strand specific to both human and mouse Cyr61 according to SEQ ID NO: 102, 104 or 105, preferably a human and mouse Cyr61 according to SEQ ID NO: 102 and a sequence complementary thereto Double-stranded oligostructures comprising specific siRNAs; or,
- Plekho1 comprising an antisense strand comprising an siRNA sense strand specific to both human and mouse Plekho1 according to SEQ ID NO: 204, 207 or 208, preferably the human and mouse Plekho1 according to SEQ ID NO: 207 Double-stranded oligostructures comprising specific siRNAs; May be included.
- the double helix oligo RNA structure comprising the CTGF-specific siRNA may be included in a mixed form.
- siRNA specific to a respiratory disease related gene other than CTGF, Cry61 or Plekho1, or a double-stranded oligo RNA structure comprising the same may be additionally included in the composition according to the present invention.
- the double helix oligo RNA construct comprising the CTGF, Cry61 and / or Plekho1 specific siRNA, additionally comprises another respiratory disease associated gene specific siRNA.
- a composition for preventing or treating a respiratory disease including all of the double-stranded oligo RNA structures synergistic effects may be obtained as in combination therapy.
- Respiratory diseases that the composition according to the present invention can prevent or treat include idiopathic pulmonary fibrosis, asthma, chronic obstructive pulmonary disease (COPD), acute bronchitis, allergic rhinitis, antitussive expectoration, acute lower respiratory tract infection (bronchitis and bronchiolitis), sore throat
- COPD chronic obstructive pulmonary disease
- Acute upper respiratory tract infections such as tonsillitis and laryngitis, may be exemplified, but is not limited thereto.
- any of the nanoparticles included in the composition for preventing or treating respiratory diseases comprising nanoparticles consisting of a double-stranded oligo RNA structure according to the present invention is selected from a double-stranded oligo RNA structure comprising CTGF, Cyr61 or Plekho1 specific siRNA. It may be purely composed of only one structure, or may be composed of a mixture of two or more double-stranded oligo RNA structures including CTGF, Cyr61 or Plekho1 specific siRNA.
- composition of the present invention may be prepared by including at least one pharmaceutically acceptable carrier in addition to the above-mentioned effective ingredient.
- Pharmaceutically acceptable carriers must be compatible with the active ingredients of the present invention and include saline solution, sterile water, Ringer's solution, buffered saline solution, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these ingredients. It can mix and use, and if needed, other conventional additives, such as antioxidant, buffer, and bacteriostatic agent, can be added.
- diluents, dispersants, surfactants, binders and lubricants may be additionally added to formulate injectable formulations such as aqueous solutions, suspensions, emulsions and the like.
- injectable formulations such as aqueous solutions, suspensions, emulsions and the like.
- it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's pharmaceutical Science, Mack Publishing Company, Easton PA.
- composition of the present invention can be determined by a person of ordinary skill in the art based on the symptoms and severity of the disease of a typical patient. It may also be formulated in various forms, such as powders, tablets, capsules, solutions, injections, ointments, syrups, and the like, and may also be provided in unit-dose or multi-dose containers, such as sealed ampoules and bottles.
- composition of the present invention can be administered orally or parenterally.
- Routes of administration of the compositions according to the invention are not limited to, for example, oral, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intestinal, sublingual Or topical administration is possible. Administration to the lungs via intrabronchial instillation is also possible, particularly for the treatment of respiratory diseases.
- the dosage of the composition according to the present invention may vary in the range depending on the weight, age, sex, health condition, diet, time of administration, method, excretion rate or severity of the disease, etc. of the patient, and is easily available to those skilled in the art. Can decide.
- the compositions of the present invention can be formulated into suitable formulations using known techniques for clinical administration.
- the present invention also provides a method for preventing and treating respiratory diseases, in particular idiopathic pulmonary fibrosis and COPD, comprising administering a double-stranded oligo RNA structure according to the present invention, and nanoparticles comprising the same to a patient in need thereof. do.
- compositions comprising CTGF, Cyr61 or Plekho1 specific siRNA according to the present invention, and double-stranded oligo RNA constructs comprising the same, inhibit the expression of CTGF, Cyr61 or Plekho1 with high efficiency without side effects, thereby respiratory diseases, in particular idiopathic pulmonary fibrosis. It can be used for the treatment of respiratory diseases, especially idiopathic pulmonary fibrosis and COPD.
- FIG. 1 is a schematic diagram of a nanoparticle consisting of a double helix oligomeric polymer structure according to the present invention.
- Figure 2 shows the confirmed target gene expression inhibition after transforming the human fibroblast cell line with siRNA having the sequence according to SEQ ID NOS 1 to 10, 101 to 110, 201 to 210 according to the present invention as a sense strand graph
- A Graph of CTGF expression according to siRNA 5 or 20 nM treatment having the sequence of SEQ ID NO: 1 to 10 as a sense strand
- A Graph of CTGF expression according to siRNA 0.2 or 1 nM treatment having the sequence number 1, 3, 4, 8, 9 or 10 as a sense strand
- RNA 4 is a human siRNA having a sense strand having a sequence according to SEQ ID NOs: 35, 42, 59, 602, 603, 604, 124, 153, 166, 187, 197, 212, 218, 221 or 223 according to the present invention.
- Figure 5 is a graph showing the target gene expression inhibitory amount confirmed after transforming human lung cancer cell lines with SAMiRNA having the sequence according to SEQ ID NO: 42, 59, 602 according to the present invention as a sense strand
- FIG. 6 is a graph showing the target gene expression inhibition rate confirmed after transforming a mouse fibroblast cell line with siRNA having a sequence of SEQ ID NOs: 301 to 330, 401 to 430, and 501 to 530 as sense strands of the present invention.
- Target gene expression inhibition graph confirmed after transforming mouse fibroblast cell line with siRNA having a sense strand
- A Graph of Cyr61 expression according to siRNA 5 nM treatment having a sense strand having a sequence of SEQ ID NOs: 404 to 406, 408 to 410, 414 to 418, 420 to 422, 424, 427, 429, and 430
- Figure 8 shows the transformation of the mouse fibroblast cell line with siRNA having the sense strand of SEQ ID NO: 301, 303, 307, 323, 410, 422, 424, 507, 515 or 525 of the present invention, and then identified the target gene Expression inhibition graph
- A Graph of CTGF expression according to 0.2, 1, 5 nM treatment of siRNA having a sequence of SEQ ID NO: 301, 303, 307 or 323 as a sense strand
- Figure 9 shows the sequence of SEQ ID NO: 4, 5, 6, 8, 9, 102, 104, 105, 107, 108, 109, 202, 204, 206 to 209, 307, 424 or 525 of the present invention as a sense strand Graph of confirmed target gene expression inhibition after transforming mouse fibroblast cell line with siRNA
- A Graph of CTGF expression according to siRNA 5nM treatment having the sequence number 4, 5, 6, 8, 9 or 307 as a sense strand
- Cyr61 expression graph according to siRNA 5nM treatment having the sequence of SEQ ID NO: 102, 104, 105, 107, 108, 109 or 424 as sense strand
- Figure 10 is confirmed after transforming the mouse fibroblast cell line with siRNA having the sequence of SEQ ID NO: 6, 8, 102, 104, 105, 204, 207, 208, 307, 424 or 525 in the sense strand of the present invention, Target Gene Expression Inhibition Graph
- A Graph of CTGF expression according to siRNA 5 or 20 nM treatment having a sequence of SEQ ID NO: 6, 8 or 307 as a sense strand
- the siRNA for the respiratory disease related gene according to the present invention is a double-stranded structure consisting of a sense strand consisting of 19 nucleotides and an antisense strand complementary thereto.
- siCONT SEQ ID NO: 601 has a sense strand
- siRNA having a sequence that does not inhibit the expression of any gene was prepared.
- the siRNA was prepared by linking phosphodiester bonds forming an RNA backbone structure using ⁇ -cyanoethyl phosphoramidite (Nucleic Acids Research, 12: 4539-4557, 1984). Specifically, using an RNA synthesizer (384 Synthesizer, BIONEER, Korea), a series of processes consisting of deblocking, coupling, oxidation, and capping on a solid support to which nucleotides are attached was repeated to obtain a reaction containing RNA of the desired length.
- RNA synthesizer 384 Synthesizer, BIONEER, Korea
- the reaction was isolated and purified by HPLC LC918 (Japan Analytical Industry, Japan) equipped with Daisogel C18 (Daiso, Japan) column and matched with target sequence using MALDI-TOF mass spectrometer (Shimadzu, Japan). Confirmed. Then, the desired double-stranded siRNA (SEQ ID NOS: 1 to 604) was prepared by combining the sense and antisense RNA strands.
- the double-stranded oligo RNA structure (PEG-SAMiRNA) prepared in the present invention has a structure as shown in the following structural formula (16).
- S is the sense strand of the siRNA
- AS is an antisense strand of siRNA
- PEG is a hydrophilic material
- polyethylene glycol is a hydrophobic material tetradocosane containing disulfide
- 5 'and 3' means the orientation of the double helix oligo RNA terminus.
- the double-stranded oligo RNA of the sense strand in which polyethylene glycol is bound to the 3 'end After synthesis of the hydrophilic material structure, the tetradocoic acid containing disulfide bond was bound to the 5 'end to prepare a sense strand of the desired RNA-polymer structure.
- the antisense strand to be annealed with the strand, the antisense strand of the sequence complementary to the sense strand was prepared through the reaction mentioned above.
- RNA single strand and RNA polymer construct synthesized by treating 28% (v / v) ammonia in a 60 ° C. water bath were separated from the CPG, and then deprotected. The protective residue was removed through.
- RNA single-stranded and RNA-polymerized structures with no protective residues were added in a volume ratio of N-methylpyrrolidon, triethylamine and triethylaminetrihydrofluoride in an oven at 70 ° C. 2 'TBDMS (tert-butuldimethylsilyl) was removed by treatment at a ratio of 10: 3: 4.
- the reaction was isolated and purified by HPLC LC918 (Japan Analytical Industry, Japan) equipped with Daisogel C18 (Daiso, Japan) column and matched with target sequence using MALDI-TOF mass spectrometer (Shimadzu, Japan). Confirmed. Then, to prepare the respective double-stranded oligo RNA structure, the same amount of the sense strand and the antisense strand were mixed by 1X annealing buffer (30 mM HEPES, 100 mM Potassium acetate, 2 mM magnesium acetate, pH 7.0).
- Double-stranded oligo RNA construct comprising siRNA having a 525 or 601 sequence as a sense strand (hereinafter referred to as SAMiRNALP-hCTGF, SAMiRNALP-hCyr, SAMiRNALP-hPlek, SAMiRNALP-mCTGF, SAMiRNALP-mCyr, SAMiRNALP-mPlek SAMiRNALP-CONT
- SAMiRNALP-hCTGF siRNA having a 525 or 601 sequence as a sense strand
- RNA structure is a hydrophilic substance is a hydrophilic material blocks the PEG rather than - the term [PO 3 - hexaethylene glycol] 4 (hereinafter, 'Mono-HEG-SAMiRNA' , structural formula (17) ) Has the same structure as the following structural formula (17).
- S is the sense strand of the siRNA
- AS is an antisense strand of siRNA
- Hexa Ethylene Glycol 4 is a hydrophilic monomer
- C 24 is a hydrophobic material tetradocosane containing disulfide
- 5 'and 3' means the orientation of the end of the double helix oligo RNA sense strand.
- the structure of the Mono-HEG SAMiRNA according to Structural Formula (17) can be represented by the following Structural Formula (18).
- the reaction was isolated and purified by HPLC LC918 (Japan Analytical Industry, Japan) equipped with Daisogel C 18 (Daiso, Japan) column and matched with target sequence using MALDI-TOF mass spectrometer (Shimadzu, Japan). It was confirmed. Then, to prepare the respective double-stranded oligo RNA structure, the same amount of the sense strand and the antisense strand were mixed by 1X annealing buffer (30 mM HEPES, 100 mM Potassium acetate, 2 mM magnesium acetate, pH 7.0).
- Double-stranded oligo RNA constructs comprising siRNA having sense strand 525 or 601 (hereinafter referred to as Mono-HEG-SAMiRNALP-hCTGF, Mono-HEG-SAMiRNALP-hCyr, Mono-HEG-SAMiRNALP-hPlek, Mono- HEG-SAMiRNALP-mCTGF, Mono-HEG-SAMiRNALP-mCyr, Mono-HEG-SAMiRNALP-mPlek, Mono-HEG-SAMiRNALP-CONT). It was confirmed that the prepared double helix oligo RNA structure was annealed through electrophoresis.
- the double-stranded oligo RNA structure (Mono-HEG-SAMiRNA) prepared in Example 3 forms nanoparticles, that is, micelles by hydrophobic interaction between hydrophobic materials bound to the ends of the double-stranded oligo RNA ( 1).
- PDI polydispersity index
- DPBS Dulbecco's Phosphate Buffered Saline
- Nanoparticles consisting of Mono-HEG-SAMiRNA-hCyr, Mono-HEG-SAMiRNA-hPlek, Mono-HEG-SAMiRNA-mCTGF, Mono-HEG-SAMiRNA-mCyr, Mono-HEG-SAMiRNA-mPlek Mono-HEG-SAMiRNA-CONT Also prepared in the same manner.
- the size of the nanoparticles was measured by zeta-potential measurement.
- the homogenized nanoparticles prepared in Example 4-1 were sized with a zeta-potentiometer (Nano-ZS, MALVERN, UK), the refractive index of the material (Refractive index) is 1.459, the absorption index is 0.001
- the temperature of 25 °C and the resulting viscosity (viscosity) of the solvent DPBS 1.0200 and the refractive index was measured by entering a value of 1.335.
- One measurement consisted of a size measurement consisting of 15 repetitions, which were repeated six times.
- the nanoparticles of the present invention were found to have a very uniform size.
- Example 5 Confirmation of expression inhibition of target gene using target gene specific siRNA for human in human fibroblast (MRC-5) cell line.
- Human fibroblasts which are fibroblast cell lines using siRNA having the sequence number 1 to 10, 101 to 110, 201 to 210 and 601 as sense strands prepared in Example 1 ) was transformed, and the expression pattern of the target gene was analyzed in the transformed fibroblast (MRC-5) cell line.
- Human fibroblast (MRC-5) cell line obtained from the Korean Cell Line Bank (KCLB) (KCLB) was cultured in RPMI-1640 culture medium (GIBCO / Invitrogen, USA, 10% (v / v) fetal bovine serum, penicillin 100 units / ml and 100 ⁇ g / ml streptomycin) were incubated at 37 ° C. under 5% (v / v) CO 2 .
- MRC-5 fetal calf serum
- RPMI 1640 5% (v / v) CO 2
- Opti-MEM medium GIBCO, USA
- RNAi Max Lipofectamine TM RNAi Max, Invitrogen, USA
- Opti-MEM medium 246.5 ⁇ l of Opti-MEM medium
- 5 or 20 ⁇ l of siRNA (1 pmole / ⁇ l) having the sequences of SEQ ID NOs: 1 to 10, 101 to 10, 201 to 210, and 601 as sense strands was added to 230 ⁇ l of Opti-MEM medium to give a final concentration of 5 or 20 nM.
- Phosphorous siRNA solution was prepared.
- the lipofectamine RNAi Max mixture and the siRNA solution were mixed and reacted at room temperature for 15 minutes to prepare a solution for transfection.
- cDNA was prepared by extracting total RNA from the cell line transfected in Example 5-2, mRNA expression of the target gene was quantified relative to each other using real-time PCR.
- Example 5-3-1 RNA Isolation and cDNA Preparation from Transfected Cells
- RNA reverse transcriptase (AccuPrep Cell total RNA extraction kit, BIONEER, Korea) the total RNA is extracted from the cell line transfected in Example 5-2, the extracted RNA is RNA reverse transcriptase (AccuPower CycleScript RT Premix / cTNA was prepared by the following method using dT20, Bioneer, Korea). Specifically, 1 ⁇ g of RNA extracted per tube was added to AccuPower CycleScript RT Premix / dT20 (Bioneer, Korea) contained in 0.25 ml Eppendorf tube, and distilled water treated with DEPC (diethyl pyrocarbonate) to have a total volume of 20 ⁇ l. Was added.
- RNA reverse transcriptase (AccuPower CycleScript RT Premix / cTNA was prepared by the following method using dT20, Bioneer, Korea). Specifically, 1 ⁇ g of RNA extracted per tube was added to AccuPower CycleScript RT Premix / dT20 (Bioneer,
- RNA and primer hybridize RNA and primer for 1 minute at 30 ° C, and repeat the two steps of preparing cDNA for 6 minutes at 52 ° C, and then at 90 ° C.
- the amplification reaction was terminated by inactivating the enzyme for 5 minutes.
- the relative amount of the mRNA associated with respiratory disease was quantified by real-time PCR in the following manner. Dilute the cDNA prepared in Example 5-3-1 with distilled water to each well of a 96-well plate with distilled water 5 times, and 3 ⁇ l of diluted cDNA and 2 ⁇ GreenStar TM PCR master mix 25 ⁇ l of BIONEER, Korea), 19 ⁇ l of distilled water, and 3 ⁇ l of qPCR primer (Table 2; F, R, 10 pmole / ⁇ l; BIONEER, Korea) were prepared.
- HK gene housekeeping gene
- RPL13A ribosomal protein L13a
- HK gene housekeeping gene
- the 96-well plate containing the mixed solution was subjected to the following reaction using Exicycler TM 96 Real-Time Quantitative Thermal Block (BIONEER, Korea) as follows: Reaction of enzyme and secondary structure of cDNA were carried out at 95 ° C. for 15 minutes. After elimination, four replicates were performed: 30 seconds denaturing at 94 ° C, 30 seconds annealing at 58 ° C, 30 seconds extension at 72 ° C, and SYBR green scan. The final extension was carried out at 72 ° C.
- the Ct (threshold cycle) value of each of the obtained target genes was obtained by calculating the Ct value of the target gene corrected through the GAPDH gene, and then siRNA of the control sequence (SEQ ID NO: 601, which does not cause gene expression inhibition). The difference of ⁇ Ct value was calculated using the experimental group treated with siCONT) as a control.
- Fig. 2.A Relative expression levels of target genes of cells treated with CTGF ( Homo sapiens ) specific siRNA (SEQ ID NOs: 1 to 10 with sense strands) were treated using the ⁇ Ct value and Formula 2 ( ⁇ Ct ) ⁇ 100. Quantification (Fig. 2.A). In addition, relative amounts of expression of target genes of cells treated with Cyr61 ( Homo sapiens ) -specific siRNA (having the sequences of SEQ ID NOs: 101 to 110) as a sense strand were compared (Fig. 2B), and Plekho1 (Homo sapiens) specificity Relative quantification of the expression level of the target gene of the cells treated with the enemy siRNA (SEQ ID NO: 201 to 210 with the sense strand) (Fig. 2C).
- siRNA of the present invention showed high target gene expression inhibition.
- the mRNA expression amount of each gene was greatly reduced at 5 nM concentrations of SEQ ID NOs: 1, 3, 4, 8, 9, 10, 102, 104, 105, 106, 107, 108, SiRNAs with sense strands of sequences 109, 204, 206, 207, 208, 209 and 210 were selected.
- MRC-5 transforming human fibroblasts
- Human fibroblast (MRC-5) cell lines obtained from the Korean Cell Line Bank (KCLB, Korea) were cultured under the same conditions as in Example 5-1.
- 1.8 ⁇ 10 5 fibroblast (MRC-5) cell line cultured in Example 6-1 was incubated in RPMI 1640 for 18 hours in a 6-well plate under conditions of 5% (v / v) CO 2 at 37 ° C. After removing the medium, 500 ⁇ l of Opti-MEM medium (GIBCO, USA) was dispensed for each well.
- RNAi Max Lipofectamine TM RNAi Max, Invitrogen, USA
- Opti-MEM medium 246.5 ⁇ l of Opti-MEM medium
- the lipofectamine RNAi Max mixture and the siRNA solution were mixed and reacted at room temperature for 15 minutes to prepare a solution for transfection.
- RNA expression amount of the target gene using real-time PCR Relative quantification Observation of the target gene expression inhibition by the low concentration of siRNA was clearly confirmed the efficacy of each siRNA, siRNA having 8, 107 and 206 as the sense strand showed relatively high target gene expression inhibition even at very low concentrations It was confirmed (Fig. 3).
- Example 7 Confirmation of expression inhibition of target gene using target gene specific siRNA for human in human lung cancer cell line (A549).
- Example 1 Human lung cancer cell line (A549), which is a lung tumor cell line, was transformed, and the expression patterns of the target genes were analyzed in the transformed lung cancer cell (A549) cell line.
- Human lung cancer cell (A549) cell lines obtained from the American Type Culture Collection (ATCC) are DMEM culture medium (GIBCO / Invitrogen, USA, 10% (v / v) fetal bovine serum, penicillin 100 units / ml and streptoto Incubated at 37 ° C., 5% (v / v) CO 2 .
- ATCC American Type Culture Collection
- Example 7-1 the 1.2 ⁇ 10 5 cancer cells (A549) cell line was incubated in DMEM for 18 hours in a 6-well plate under conditions of 5% (v / v) CO 2 at 37 ° C., and then the medium was removed. Each well was dispensed with 500 ⁇ l of Opti-MEM medium (GIBCO, USA).
- RNAi Max (Invitrogen, USA) and 246.5 ⁇ l of Opti-MEM medium were mixed to prepare a mixed solution, reacted for 5 minutes at room temperature, and then prepared in Example 1, respectively.
- RNA expression amount of the target gene was quantified by real-time PCR.
- Example 7-3-1 RNA Isolation and cDNA Preparation from Transfected Cells
- RNA reverse transcriptase (AccuPrep Cell total RNA extraction kit, BIONEER, Korea) the total RNA is extracted from the cell line transfected in Example 5-2, the extracted RNA is RNA reverse transcriptase (AccuPower CycleScript RT Premix / cTNA was prepared by the following method using dT20, Bioneer, Korea). Specifically, 1 ⁇ g of RNA extracted per tube was added to AccuPower CycleScript RT Premix / dT20 (Bioneer, Korea) contained in 0.25 ml Eppendorf tube, and distilled water treated with DEPC (diethyl pyrocarbonate) to have a total volume of 20 ⁇ l. Was added.
- RNA reverse transcriptase (AccuPower CycleScript RT Premix / cTNA was prepared by the following method using dT20, Bioneer, Korea). Specifically, 1 ⁇ g of RNA extracted per tube was added to AccuPower CycleScript RT Premix / dT20 (Bioneer,
- RNA and primer hybridize RNA and primer for 1 minute at 30 ° C, and repeat the two steps of preparing cDNA for 6 minutes at 52 ° C, and then at 90 ° C.
- the amplification reaction was terminated by inactivating the enzyme for 5 minutes.
- the relative amount of respiratory disease-associated gene mRNA was quantified by real-time PCR in the following manner. Dilute the cDNA prepared in Example 6-3-1 with distilled water five times in each well of a 96-well plate, and 3 ⁇ l of the diluted cDNA and 2 ⁇ GreenStar TM PCR master mix for analysis of target gene mRNA levels. 25 ⁇ l of BIONEER, Korea), 19 ⁇ l of distilled water, and 3 ⁇ l of qPCR primer (Table 2; F, R, 10 pmole / ⁇ l; BIONEER, Korea) were prepared.
- HK gene housekeeping gene
- RPL13A ribosomal protein L13a
- HK gene housekeeping gene
- the 96-well plate containing the mixed solution was subjected to the following reaction using Exicycler TM 96 Real-Time Quantitative Thermal Block (BIONEER, Korea) as follows: Reaction of enzyme and secondary structure of cDNA were carried out at 95 ° C. for 15 minutes. After elimination, four replicates were performed: 30 seconds denaturing at 94 ° C, 30 seconds annealing at 58 ° C, 30 seconds extension at 72 ° C, and SYBR green scan. The final extension was carried out at 72 ° C.
- the obtained Ct (threshold cycle) value of each target gene is obtained by measuring the Ct value of the target gene corrected through the GAPDH gene, and then siRNA of the control sequence that does not cause gene expression inhibition (SEQ ID NO: 601, The difference of ⁇ Ct value was calculated using the experimental group treated with siCONT) as a control.
- siRNA of the present invention showed high target gene expression inhibition. Further, in order to select high efficiency siRNAs, mRNA expressions for each gene were greatly reduced at 5Nm and 5nM concentrations, SEQ ID NOs: 42, 59, 602, 124, 153, 187, 197, 212, 218, 221 and 223 SiRNAs were selected with the sense strand as the sequence.
- the particles were transformed into human lung cancer cells (A549) and analyzed for expression of target genes in the transformed lung cancer cells (A549) cell line.
- Human lung cancer (A549) cell lines obtained from the American Type Culture Collection (ATCC) were cultured under the same conditions as in Example 7-1.
- the 1.2 ⁇ 10 5 cancer cell (A549) cell line cultured in Example 8-1 was incubated in RPMI 1640 for 18 hours in a 12-well plate under conditions of 5% (v / v) CO 2 at 37 ° C., After removing the medium, an equal amount of Opti-MEM medium (GIBCO, USA) was dispensed per well. 100 ⁇ l of Opti-MEM medium and SAMiRNALP and monoSAMiRNALP prepared in Example 4-2 were added to DPBS at a concentration of 50 ⁇ g / ml, and the result was 48 hours at ⁇ 75 ° C. and 5 mTorr conditions in the same manner as in Example 5-1. Lyophilization during to prepare uniform nanoparticles.
- RNA expression amount of the target gene using real-time PCR Relative quantification Observation of the target gene expression by the low concentration of siRNA was able to clearly confirm the efficacy of each siRNA, siRNA having 42, 59 and 602 as the sense strand showed relatively high target gene expression inhibition even at very low concentration It was confirmed that (Fig. 5).
- Mouse fibroblasts which is a fibroblast cell line, using siRNAs having the sense strands of SEQ ID NOs: 301 to 330, 401 to 430, 501 to 530, and 601 prepared in Example 1 as strands After the transformation, the expression patterns of the target genes were analyzed in the transformed fibroblast (NIH3T3) cell line.
- Mouse fibroblast (NIH3T3) cell line obtained from the American Type Culture Collection (ATCC) was prepared using RPMI-1640 culture medium (GIBCO / Invitrogen, USA, 10% (v / v) fetal bovine serum, penicillin 100 units / ml And 100 ⁇ g / ml) of streptomycin at 37 ° C. under 5% (v / v) CO 2 .
- fibroblast (NIH3T3) cell line cultured in Example 9-1 was incubated in RPMI 1640 for 18 hours in a 12-well plate under conditions of 5% (v / v) CO 2 at 37 ° C., After removing the medium, 500 ⁇ l of Opti-MEM medium (GIBCO, USA) was dispensed for each well.
- RNAi Max Lipofectamine TM RNAi Max, Invitrogen, USA
- Opti-MEM medium 248.5 ⁇ l of Opti-MEM medium
- 5 or 20 ⁇ l of siRNA (1 pmole / ⁇ l) having the sequences of SEQ ID NOs: 301 to 330, 401 to 430, 501 to 530 and 601 as sense strands was added to 230 ⁇ l of Opti-MEM medium to give a final concentration of 5 or
- a siRNA solution of 20 nM was prepared.
- the lipofectamine RNAi Max (Lipofectamine TM RNAi Max) mixture and the siRNA solution were mixed and reacted for 20 minutes at room temperature to prepare a solution for transfection.
- the expression levels of target genes of cells treated with CTGF ( Mus musculus ) -specific siRNA were relatively quantified (FIG. 6A).
- the relative amount of expression of the target gene of the cells treated with Cyr61 ( Mus musculus ) specific siRNA was relatively quantified (FIG. 6B)
- Plekho1 ( Mus musculus ) specificity was relative quantitative (Fig. 6C).
- siRNA of the present invention showed high target gene expression inhibition.
- SiRNA having the sense strand was selected, and the sequence of SEQ ID Nos. 409, 410, 415, 417, 418, 420, 422, 424, 427 or 429 was reduced in the amount of mRNA expression for Cyr61 ( Mus musculus ).
- SiRNA was selected, and the sense strand containing the sequence of SEQ ID NOs 504, 505, 506, 507, 514, 515, 522, 523, 524, or 525 with a high decrease in mRNA expression for Plekho1 ( Mus musculus ) siRNA was selected.
- siRNA having a sense strand having a sequence of SEQ ID NO: 301, 303, 307, or 323 with a high reduction in mRNA expression for CTGF ( Mus musculus ) at 5 nM concentration was selected to select siRNAs having more desirable efficiency.
- Plekho1 (Mus musculus) mRNA expression amount is decreased higher sequence number for the SiRNAs with the sense strand of sequence 507, 515 or 525 were selected (FIG. 7).
- the high efficiency siRNA was selected by analyzing the expression pattern of the target gene in.
- NIH3T3 Mouse fibroblast (NIH3T3) cell lines obtained from the American Type Culture Collection (ATCC) were cultured under the same conditions as in Example 9-1.
- Example 10-1 1 ⁇ 10 5 fibroblasts (NIH3T3) cell line cultured in Example 10-1 was incubated in RPMI 1640 for 18 hours in a 12-well plate under conditions of 5% (v / v) CO 2 at 37 ° C., After removing the medium, 500 ⁇ l of Opti-MEM medium (GIBCO, USA) was dispensed for each well.
- Opti-MEM medium GIBCO, USA
- RNAi Max Lipofectamine TM RNAi Max, Invitrogen, USA
- Opti-MEM medium 248.5 ⁇ l of Opti-MEM medium
- SiRNA solutions having a final concentration of 0.2, 1 or 5 nM were prepared.
- the lipofectamine RNAi Max (Lipofectamine TM RNAi Max) mixture and the siRNA solution were mixed and reacted for 20 minutes at room temperature to prepare a solution for transfection.
- siRNAs having the sense strands of SEQ ID NOs: 307, 424, and 525 as the sense strands had relatively high target gene expression inhibition even at very low concentrations. It was confirmed that the effect was maintained and was selected as a high efficiency siRNA.
- the site of action of the bionew drug is mainly species-specific such as protein structure or gene sequence
- the identity of the therapeutic drug is very important for securing efficiency in the bionew drug development process.
- Gene sequence homology between the target gene-specific siRNA and the mouse target gene for humans designed in Example 1 was selected to determine siRNA sequences to confirm target gene expression inhibition effects in mouse fibroblasts.
- the selected siRNA sequence is SEQ ID NO: 4, 5, 6 8 9, 102, 104, 105, 107, 108, 109, 202, 204, 206, 207 which is a target gene specific siRNA for humans prepared in Example 1 above.
- the expression patterns of target genes were analyzed in mouse fibroblast (NIH3T3) cell line, which is a fibroblast cell line, to confirm the efficacy in mouse cells of siRNAs designed based on human genes.
- NIH3T3 Mouse fibroblast (NIH3T3) cell lines obtained from the American Type Culture Collection (ATCC) were cultured under the same conditions as in Example 9-1.
- the 1.8 ⁇ 10 5 fibroblast (NIH3T3) cell line cultured in Example 11-1 was incubated in RPMI 1640 for 18 hours in a 6-well plate under conditions of 5% (v / v) CO 2 at 37 ° C., After removing the medium, 500 ⁇ l of Opti-MEM medium (GIBCO, USA) was dispensed for each well.
- RNAi Max Lipofectamine TM RNAi Max, Invitrogen, USA
- Opti-MEM medium 246.5 ⁇ l of Opti-MEM medium
- the lipofectamine RNAi Max mixture and the siRNA solution were mixed and reacted at room temperature for 15 minutes to prepare a solution for transfection.
- mRNA expression amount of the target gene using real-time PCR (real-time PCR) Relative quantification Relative quantitative expression of target gene expression in cells treated with CTGF ( Mus musculus ) specific siRNA (SEQ ID NO: 307) or CTGF ( Homo sapiens ) specific siRNA (SEQ ID NO: 4, 5, 6, 8, or 9) (FIG. 9A).
- Cyr61 ( Mus musculus ) specific siRNA (SEQ ID NO: 424 has a sense strand) or Cyr61 ( Homo sapiens ) specific siRNA (SEQ ID NO: 102, 104, 105, 107, 108 or 109 sequences Expression level of the target gene of the treated cells (Fig. 9B), Plekho1 ( Mus musculus ) specific siRNA (SEQ ID NO: 525 has a sense strand) or Plekho1 ( Homo sapiens ) specific Relative quantification of the expression levels of target genes in cells treated with siRNA (SEQ ID NO: 202, 204, 206, 207, 208 or 209 with sense strands) was performed (FIG. 9C).
- the target gene-specific siRNAs for each human inhibited the expression of the target gene according to sequence homology, and SEQ ID NOs: 6, 8, 102, 104, 105, 204, 207, and 208
- the siRNA having the sense strand as the sequence showed relatively high target gene expression inhibition at 20 nM.
- the siRNAs of 6, 102 and 207 were found to have an IC50 (inhibition concentration 50%) of less than 20 nM even in mouse cell lines.
- IC50 inhibition concentration 50%
Abstract
Description
Claims (36)
- 서열번호 1 내지 600 및 서열번호 602 내지 604로 구성된 군에서 선택된 어느 하나의 서열을 포함하는 센스가닥(sense strand)과 이에 상보적 서열을 포함하는 안티센스 가닥으로 이루어진 CTGF, Cyr61 또는 Plekho1 특이적 siRNA.
- 제1항에 있어서,siRNA의 센스가닥 또는 안티센스 가닥은 19 내지 31개의 뉴클레오타이드로 이루어진 것을 특징으로 하는 CTGF, Cyr61 또는 Plekho1 특이적 siRNA.
- 제 1항에 있어서,서열번호 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 35, 42, 59, 101, 102, 103, 104, 105, 106, 107, 108, 109. 110, 124, 153, 166, 187, 197, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 212, 218, 221, 223, 301, 302, 303, 305, 306, 307, 309, 317, 323, 329, 409, 410, 415, 417, 418, 420, 422, 424, 427, 429, 504, 505, 506, 507, 514, 515, 522, 523, 524, 525, 602, 603 및 604번으로 구성된 군에서 선택된 어느 하나의 서열을 포함하는 센스가닥과 이에 상보적 서열을 포함하는 안티센스 가닥을 포함하는 CTGF, Cyr61 또는 Plekho1 특이적 siRNA.
- 제 1항 내지 제 3항 중 어느 한 항에 있어서,siRNA의 센스가닥 또는 안티센스 가닥은 하나 이상의 화학적 변형(chemical modification)을 포함하는 것을 특징으로 하는 CTGF, Cyr61 또는 Plekho1 특이적 siRNA.
- 제 4항에 있어서,상기 화학적 변형은뉴클레오티드 내 당 구조의 2´ 탄소 위치에서 -OH기가 -CH3(메틸), -OCH3(methoxy), -NH2, -F(불소), -O-2-메톡시에틸 -O-프로필(propyl), -O-2-메틸티오에틸(methylthioethyl), -O-3-아미노프로필, -O-3-디메틸아미노프로필, -O-N-메틸아세트아미도 또는 -O-디메틸아미도옥시에틸로의 치환에 의한 변형;뉴클레오티드 내 당(sugar) 구조 내의 산소가 황으로 치환된 변형;뉴클레오티드결합의 포스포로티오에이트(phosphorothioate) 또는 보라노포페이트(boranophosphate), 메틸포스포네이트(methyl phosphonate) 결합으로의 변형;PNA(peptide nucleic acid), LNA(locked nucleic acid) 또는 UNA(unlocked nucleic acid) 형태로의 변형;에서 선택된 하나 이상의 변형임을 특징으로 하는 CTGF, Cyr61 또는 Plekho1 특이적 siRNA.
- 제1항 내지 제5항 중 어느 한 항에 있어서,siRNA의 안티센스 가닥의 5’ 말단에 하나 이상의 인산기(phosphate group(s))가 결합되어 있는 것을 특징으로 하는 CTGF, Cyr61 또는 Plekho1 특이적 siRNA.
- 제7항 내지 제9항 중 어느 한 항에 있어서,CTGF, Cyr61 또는 Plekho1 특이적 siRNA는 제1항 내지 제6항 중 어느 한 항에 따른 siRNA 임을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제7항 내지 제10항 중 어느 한 항에 있어서,친수성 물질의 분자량은 200 내지 10,000 임을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제11항에 있어서,친수성 물질은 폴리에틸렌 글리콜(PEG), 폴리비닐피롤리돈 및 폴리옥사졸린으로 구성된 군에서 선택되는 어느 하나 임을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제7항 내지 제10항 중 어느 한 항에 있어서,친수성 물질은 하기 구조식 (5) 또는 구조식 (6)의 구조를 갖는 것을 특징으로 하는 이중나선 올리고 RNA 구조체.구조식 5구조식 6상기 구조식 (5) 및 구조식 (6)에서 A’은 친수성 물질 단량체(monomer)를, J는 m개의 친수성 물질 단량체 간 또는 m개의 친수성 물질 단량체와 siRNA를 서로 연결하는 링커, m은 1 내지 15의 정수, n은 1 내지 10의 정수를 의미하며,친수성 물질 단량체 A’은 하기 화합물 (1) 내지 화합물 (3)에서 선택된 어느 하나의 화합물이며, 링커(J)는 PO3 -, SO3 및 CO2로 구성된 군에서 선택된다.
- 제7항 내지 제10항 중 어느 한 항에 있어서,상기 소수성 물질의 분자량은 250 내지 1,000인 것을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제14항에 있어서,소수성 물질은 스테로이드(steroid) 유도체, 글리세라이드(glyceride) 유도체, 글리세롤 에테르(glycerol ether), 폴리프로필렌 글리콜(polypropylene glycol), C12 내지 C50의 불포화 또는 포화탄화수소(hydrocarbon), 디아실포스파티딜콜린(diacylphosphatidylcholine), 지방산(fatty acid), 인지질(phospholipid) 및 리포폴리아민(lipopolyamine)으로 구성된 군에서 선택되는 것을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제15항에 있어서,상기 스테로이드(steroid) 유도체는 콜레스테롤, 콜리스탄올, 콜산, 콜리스테릴 포르메이트, 코테스타닐 포르메이트 및 콜리스타닐아민으로 구성된 군에서 선택되는 것을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제15항에 있어서,상기 글리세라이드 유도체는 모노-, 디- 및 트리-글리세라이드에서 선택되는 것을 특징으로 하는 이중나선 올리고 RNA 구조체
- 제7항 내지 제17항 중 어느 한 항에 있어서,상기 X 및 Y로 표시되는 공유결합은 비분해성 결합 또는 분해성 결합인 것을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제18항에 있어서,상기 비분해성 결합은 아미드 결합 또는 인산화 결합인 것을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제18항에 있어서,상기 분해성 결합은 이황화 결합, 산분해성 결합, 에스테르 결합, 안하이드라이드 결합, 생분해성 결합 또는 효소 분해성 결합인 것을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제7항 내지 제20항 중 어느 한 항에 있어서,친수성 물질에 수용체 매개 내포작용(receptor-mediated endocytosis, RME)을 통해 타겟 세포 내재화(internalization)를 증진시키는 수용체와 특이적으로 결합하는 특성을 가진 리간드(ligand)가 추가적으로 결합된 것을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제21항에 있어서,상기 리간드는 타겟 수용체 특이적 항체나 앱타머, 펩타이드, 엽산(folate), N-아세틸 갈락토사민(N-acetyl Galactosamine, NAG), 포도당(glucose) 및 만노스(mannose) 로 구성된 군에서 선택되는 것을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제7항 내지 제20항 중 어느 한 항에 있어서,상기 친수성 물질의 siRNA와 결합된 반대편 말단 부위에 아민기 또는 폴리히스티딘(polyhistidine) 그룹이 추가적으로 도입된 것을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제23항에 있어서,상기 아민기 또는 폴리히스티딘(polyhistidine) 그룹은 하나 이상의 링커를 통해 친수성 물질 또는 친수성 블록과 연결된 것을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제23항에 있어서,상기 1차 내지 3차 아민기 중에서 선택된 어느 하나 임을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제23항에 있어서,상기 폴리히스티딘(polyhistidine) 그룹은 3 내지 10개의 히스티딘을 포함하는 것을 특징으로 하는 이중나선 올리고 RNA 구조체.
- 제7항 내지 제26항 중 어느 한 항에 따른 이중나선 올리고 RNA 구조체를 포함하는 나노입자(nanoparticle).
- 제27항에 있어서,서로 다른 서열을 가지는 siRNA를 포함하는 이중나선 올리고 RNA 구조체가 혼합되어 구성되는 것을 특징으로 하는 나노입자.
- 제1항 내지 제6항 중 어느 한 항에 따른 siRNA, 제7항 내지 제26항 중 어느 한 항에 따른 이중나선 올리고 RNA 구조체, 또는 제27항 또는 제28항에 따른 나노입자를 유효성분으로 포함하는 약학적 조성물.
- 제29항에 있어서,호흡기 질환의 예방 또는 치료를 위한 약학적 조성물.
- 제30항에 있어서, 상기 호흡기 질환은 천식, 특발성폐섬유화증, 만성폐쇄성폐질환(COPD), 급만성기관지염, 알레르기 비염, 진해 거담, 급성하기도 감염증, 기관지염, 세기관지염, 급성상기도감염증, 인후염, 편도염 및 후두염으로 이루어진 군에서 선택되는 것을 특징으로 하는 약학적 조성물.
- 제30항에 있어서,상기 호흡기 질환은 특발성폐섬유화증 또는 만성폐쇄성폐질환(COPD) 임을 특징으로 하는 약학적 조성물.
- 제29항 내지 제32항 중 어느 한 항에 따른 조성물을 포함하는 동결건조된 형태의 제형.
- 제1항 내지 제33항 중 어느 한 항에 따른 siRNA, 이중나선 올리고 RNA 구조체, 나노입자, 조성물 또는 제형을 예방 또는 치료를 요하는 개체에게 투여하는 것을 특징으로 하는 호흡기 질환의 예방 또는 치료 방법.
- 제34항에 있어서,상기 호흡기 질환은 천식, 특발성폐섬유화증, 만성폐쇄성폐질환(COPD), 급만성기관지염, 알레르기 비염, 진해 거담, 급성하기도 감염증, 기관지염, 세기관지염, 급성상기도감염증, 인후염, 편도염 및 후두염으로 이루어진 군에서 선택되는 것을 특징으로 하는 호흡기 질환의 예방 또는 치료 방법.
- 제35항에 있어서,상기 호흡기 질환은 특발성폐섬유화증 또는 만성폐쇄성폐질환(COPD) 임을 특징으로 하는 호흡기 질환의 예방 또는 치료 방법.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016523670A JP2016525346A (ja) | 2013-07-05 | 2014-07-04 | 呼吸器疾患関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体およびこれを含む呼吸器疾患予防または治療用組成物 |
RU2016103695A RU2656154C2 (ru) | 2013-07-05 | 2014-07-04 | СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ |
US14/902,566 US20160122764A1 (en) | 2013-07-05 | 2014-07-04 | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease |
BR112016000163A BR112016000163A2 (pt) | 2013-07-05 | 2014-07-04 | sirna específico de gene relacionado à doença respiratória, estrutura de oligo rna de dupla-hélice oligo contendo o sirna, composição contendo os mesmos para prevenir ou tratar doença respiratória |
EP14820458.9A EP3018209B1 (en) | 2013-07-05 | 2014-07-04 | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease |
CN201480048988.7A CN105683377B (zh) | 2013-07-05 | 2014-07-04 | 呼吸疾病相关基因特异性siRNA、含有siRNA的双螺旋寡RNA结构、含有它们的组合物用于预防或治疗呼吸疾病 |
KR1020167002234A KR101867414B1 (ko) | 2013-07-05 | 2014-07-04 | 호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물 |
AU2014284836A AU2014284836B2 (en) | 2013-07-05 | 2014-07-04 | Respiratory disease-related gene specific siRNA, double-helical oligo RNA structure containing siRNA, compositon containing same for preventing or treating respiratory disease |
CA2917320A CA2917320C (en) | 2013-07-05 | 2014-07-04 | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, composition containing same for preventing or treating respiratory disease |
MX2016000019A MX2016000019A (es) | 2013-07-05 | 2014-07-04 | (arnip) gen especifico relacionado con las enfermedades respiratorias, (arnip) que contiene la estructura arn oligo helicoidal, composicion que contiene la misma para prevencion o tratamiento de las enfermedades respiratorias. |
EP19180054.9A EP3591053A1 (en) | 2013-07-05 | 2014-07-04 | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130079311 | 2013-07-05 | ||
KR10-2013-0079311 | 2013-07-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015002513A2 true WO2015002513A2 (ko) | 2015-01-08 |
WO2015002513A3 WO2015002513A3 (ko) | 2015-03-05 |
Family
ID=52144252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/006033 WO2015002513A2 (ko) | 2013-07-05 | 2014-07-04 | 호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160122764A1 (ko) |
EP (2) | EP3591053A1 (ko) |
JP (3) | JP2016525346A (ko) |
KR (1) | KR101867414B1 (ko) |
CN (3) | CN110592083A (ko) |
AU (1) | AU2014284836B2 (ko) |
BR (1) | BR112016000163A2 (ko) |
CA (1) | CA2917320C (ko) |
MX (1) | MX2016000019A (ko) |
RU (1) | RU2656154C2 (ko) |
WO (1) | WO2015002513A2 (ko) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017178883A3 (en) * | 2016-04-11 | 2018-08-23 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor |
US10590423B2 (en) | 2015-11-16 | 2020-03-17 | Olix Pharmaceuticals, Inc. | Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3 |
US10829760B2 (en) | 2010-10-22 | 2020-11-10 | Olix Pharmaceuticals, Inc. | Nucleic acid molecules inducing RNA interference, and uses thereof |
US10883105B2 (en) | 2012-05-22 | 2021-01-05 | Olix Pharmaceuticals, Inc. | RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor |
US10947541B2 (en) | 2016-02-02 | 2021-03-16 | Olix Pharmaceuticals, Inc. | Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1 |
US11040057B2 (en) | 2016-06-29 | 2021-06-22 | Olix Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for potentiating gene silencing |
US11591600B2 (en) | 2017-02-10 | 2023-02-28 | OliX Pharmaceuticals. Inc. | Long double-stranded RNA for RNA interference |
EP4063504A4 (en) * | 2019-11-22 | 2024-03-06 | Bioneer Corp | CTGF GENE SPECIFIC DOUBLE STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION AND TREATMENT OF FIBROTIC DISEASES AND RESPIRATORY DISEASES COMPRISING THE SAME |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108779464B (zh) | 2016-02-02 | 2022-05-17 | 奥利克斯医药有限公司 | 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病 |
KR101861738B1 (ko) * | 2016-08-24 | 2018-05-29 | (주)바이오니아 | 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체 |
CN108251420A (zh) * | 2016-12-28 | 2018-07-06 | 苏州瑞博生物技术有限公司 | 抑制人和动物中CTGF基因表达的siRNA、包含其的组合物及其应用 |
WO2019047914A1 (zh) | 2017-09-07 | 2019-03-14 | 北京泰德制药股份有限公司 | 靶向ckip-1的双链rna分子及其用途 |
KR102141124B1 (ko) * | 2018-01-30 | 2020-08-04 | (주)바이오니아 | 이중 가닥 miRNA를 포함하는 이중나선 올리고뉴클레오타이드 구조체 및 이의 용도 |
KR101993894B1 (ko) * | 2018-05-21 | 2019-06-28 | (주)바이오니아 | 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체 |
KR20200014684A (ko) * | 2018-07-31 | 2020-02-11 | 주식회사 레모넥스 | Ctgf 발현 억제용 조성물 |
CN109402127B (zh) * | 2018-09-29 | 2021-12-10 | 复旦大学附属眼耳鼻喉科医院 | 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用 |
KR102473989B1 (ko) * | 2018-11-28 | 2022-12-07 | (주)바이오니아 | 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물 |
WO2020149644A1 (ko) * | 2019-01-15 | 2020-07-23 | (주)바이오니아 | Dkk1 유전자를 표적으로 하는 이중나선 올리고뉴클레오티드, 이를 포함하는 구조체 및 이를 포함하는 탈모 예방 또는 발모용 조성물 |
CN116157158A (zh) * | 2020-05-14 | 2023-05-23 | 柏业公司 | 用于预防或治疗肥胖症相关疾病的含有双调蛋白特异性双链寡核苷酸结构的组合物 |
EP4306133A1 (en) * | 2021-03-08 | 2024-01-17 | Bioneer Corporation | Composition for administration of double-stranded oligonucleotide structures using ultrasonic nebulizer for prevention or treatment of respiratory viral infection including covid-19, pulmonary fibrosis caused by viral infection, or respiratory diseases |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US5808023A (en) | 1990-07-27 | 1998-09-15 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides |
US6175001B1 (en) | 1998-10-16 | 2001-01-16 | The Scripps Research Institute | Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same |
US6326358B1 (en) | 1998-07-14 | 2001-12-04 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
US6531584B1 (en) | 1990-01-11 | 2003-03-11 | Isis Pharmaceuticals, Inc. | 2'modified oligonucleotides |
KR100883471B1 (ko) | 2005-08-17 | 2009-02-16 | (주)바이오니아 | siRNA의 세포내 전달을 위한 siRNA와 친수성 고분자 간의접합체 및 그의 제조방법 |
US7622454B2 (en) | 2004-12-23 | 2009-11-24 | Alcon, Inc. | RNAi inhibition of CTGF for treatment of ocular disorders |
US20120164151A1 (en) | 2009-07-02 | 2012-06-28 | Fibrogen, Inc. | Methods for Treatment of Muscular Dystrophy |
KR20120119212A (ko) | 2012-10-15 | 2012-10-30 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
KR101224828B1 (ko) | 2009-05-14 | 2013-01-22 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000036100A1 (en) * | 1998-12-17 | 2000-06-22 | The University Of Western Ontario | Protein kinase targeting protein |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US8258105B2 (en) * | 2003-10-07 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides optimized for kidney targeting |
US7374927B2 (en) * | 2004-05-03 | 2008-05-20 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Rna干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
PL1905451T3 (pl) * | 2004-05-31 | 2010-05-31 | Almirall Sa | Kombinacje obejmujące środki przeciwmuskarynowe i kortykosteroidy |
WO2006023491A2 (en) * | 2004-08-16 | 2006-03-02 | The Cbr Institute For Biomedical Research, Inc. | Method of delivering rna interference and uses thereof |
US7825099B2 (en) * | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
JP2010507387A (ja) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のsiRNAおよびその使用方法 |
WO2009126933A2 (en) * | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
US20120016011A1 (en) * | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
CN104922676B (zh) * | 2009-03-20 | 2019-03-12 | Clsn实验室股份有限公司 | 聚胺衍生物 |
KR101179471B1 (ko) * | 2009-05-12 | 2012-09-07 | 한국과학기술연구원 | 자기 집합체 고분자 나노입자를 이용한 siRNA 전달 시스템 |
CN101708328A (zh) | 2009-11-06 | 2010-05-19 | 上海市免疫学研究所 | Cyr61蛋白在制药中的应用 |
JP6060071B2 (ja) * | 2010-03-24 | 2017-01-11 | アールエックスアイ ファーマシューティカルズ コーポレーション | 皮膚および線維症適用におけるrna干渉 |
US20140134181A1 (en) * | 2010-11-05 | 2014-05-15 | Kenneth E. Lipson | Treatment Method For Lung Remodeling Diseases |
CN102824647B (zh) * | 2011-06-13 | 2014-07-23 | 香港中文大学 | 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法 |
WO2013059496A1 (en) * | 2011-10-18 | 2013-04-25 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
PL2796150T3 (pl) * | 2011-12-15 | 2021-08-30 | Bioneer Corporation | Nowe koniugaty oligonukleotydowe i ich zastosowanie |
KR20130068032A (ko) * | 2011-12-15 | 2013-06-25 | (주)바이오니아 | 안정한 안티센스 올리고뉴클레오티드 접합체 및 그 제조방법 |
CN107988227A (zh) * | 2012-01-05 | 2018-05-04 | 株式会社百奥尼 | 高效率的纳米颗粒型双螺旋寡rna结构体及其制备方法 |
CN102793910A (zh) * | 2012-06-07 | 2012-11-28 | 中国航天员科研训练中心 | Ckip-1蛋白及其编码基因的新用途 |
JP2015532100A (ja) * | 2012-10-05 | 2015-11-09 | バイオニア コーポレイション | アンフィレギュリンに特異的な二重鎖オリゴrna、そのような二重鎖オリゴrnaを含む二重鎖オリゴrnaの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物 |
-
2014
- 2014-07-04 MX MX2016000019A patent/MX2016000019A/es unknown
- 2014-07-04 WO PCT/KR2014/006033 patent/WO2015002513A2/ko active Application Filing
- 2014-07-04 CA CA2917320A patent/CA2917320C/en active Active
- 2014-07-04 EP EP19180054.9A patent/EP3591053A1/en not_active Withdrawn
- 2014-07-04 RU RU2016103695A patent/RU2656154C2/ru active
- 2014-07-04 US US14/902,566 patent/US20160122764A1/en not_active Abandoned
- 2014-07-04 CN CN201910357348.9A patent/CN110592083A/zh active Pending
- 2014-07-04 JP JP2016523670A patent/JP2016525346A/ja active Pending
- 2014-07-04 AU AU2014284836A patent/AU2014284836B2/en active Active
- 2014-07-04 CN CN201910356447.5A patent/CN110592082A/zh active Pending
- 2014-07-04 KR KR1020167002234A patent/KR101867414B1/ko active IP Right Grant
- 2014-07-04 BR BR112016000163A patent/BR112016000163A2/pt active IP Right Grant
- 2014-07-04 EP EP14820458.9A patent/EP3018209B1/en active Active
- 2014-07-04 CN CN201480048988.7A patent/CN105683377B/zh active Active
-
2017
- 2017-07-10 JP JP2017134539A patent/JP6677679B2/ja active Active
-
2019
- 2019-12-06 JP JP2019220825A patent/JP6899509B2/ja active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6531584B1 (en) | 1990-01-11 | 2003-03-11 | Isis Pharmaceuticals, Inc. | 2'modified oligonucleotides |
US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US5958691A (en) | 1990-06-11 | 1999-09-28 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
US5808023A (en) | 1990-07-27 | 1998-09-15 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides |
US6326358B1 (en) | 1998-07-14 | 2001-12-04 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
US6175001B1 (en) | 1998-10-16 | 2001-01-16 | The Scripps Research Institute | Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same |
US7622454B2 (en) | 2004-12-23 | 2009-11-24 | Alcon, Inc. | RNAi inhibition of CTGF for treatment of ocular disorders |
KR100883471B1 (ko) | 2005-08-17 | 2009-02-16 | (주)바이오니아 | siRNA의 세포내 전달을 위한 siRNA와 친수성 고분자 간의접합체 및 그의 제조방법 |
KR101224828B1 (ko) | 2009-05-14 | 2013-01-22 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
US20120164151A1 (en) | 2009-07-02 | 2012-06-28 | Fibrogen, Inc. | Methods for Treatment of Muscular Dystrophy |
KR20120119212A (ko) | 2012-10-15 | 2012-10-30 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
Non-Patent Citations (30)
Title |
---|
"Chronic obstructive pulmonary disease (COPD) treatment guidelines", CHRONIC OBSTRUCTIVE AIRWAY DISEASE CLINICAL RESEARCH CENTER, 2005, pages 30 - 31 |
"chronic obstructive pulmonary disease (COPD) treatment guidelines", CHRONIC OBSTRUCTIVE AIRWAY DISEASE CLINICAL RESEARCH CENTER, 2005, pages 52 - 58 |
"Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo", BIOCHEM. BIOPHYS. RES. COMMUN, vol. 296, 2002, pages 1000 - 1004 |
"Harnessing In Vivo siRNA Delivery for Drug Discovery and Therapeutic Development", DRUG DISCOV. TODAY, vol. 11, no. 1-2, January 2006 (2006-01-01), pages 67 - 73 |
"Nonviral delivery of synthetic siRNA s in vivo", J CLIN INVEST., vol. 117, no. 12, 3 December 2007 (2007-12-03), pages 3623 - 3632 |
"Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte selective gene transfer in human hepatoma HepG2 cells", J. CONTROLLED RELEASE, vol. 118, pages 262 - 270 |
"NUCLEIC-ACID THERAPEUTICS: BASIC PRINCIPLES AND RECENT APPLICATIONS", NATURE REVIEWS DRUG DISCOVERY, vol. 1, 2002, pages 503 - 514 |
"Progress Towards in Vivo Use of siRNAs", MOLECULAR THERAPY, vol. 13, no. 4, 2006, pages 664 - 670 |
"Silence of the transcripts: RNA interference in medicine", J. MOL. MED., vol. 83, 2005, pages 764 - 773 |
ANN. REV. MED., vol. 55, 2004, pages 61 - 65 |
BIOORG. MED. CHEM. LETT., vol. 14, 2003, pages 1139 - 1143 |
BRIGSTOCK DR: "Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals", J CELL COMMUN SIGNAL, vol. 4, no. 1, 2010, pages 1 - 4 |
DENIS G. BOSC ET AL.: "Identification and Characterization of CKIP-1, a Novel Pleckstrin Homology Domain-containing Protein That Interacts with Protein Kinase CK2", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, 2000, pages 14295 - 14306 |
F. M. VERONESE: "Peptide and protein PEGylation: a review of problems and solutions", BIOMATERIALS, vol. 22, 2001, pages 405 - 417 |
FRANCESCO M: "Veronese and Gianfranco Pasut. PEGylation, successful approach to drug delivery", DRUG DISCOVERY TODAY, vol. 10, no. 21, 2005, pages 1451 - 1458 |
J. CONTROL RELEASE, vol. 129, no. 2, 2008, pages 107 - 16 |
LINGQIANG ZHANG ET AL.: "Role for the pleckstrin homology domain containing protein CKIP-1 in AP-1 regulation and apoptosis", THE EMBO JOURNAL, vol. 24, 2005, pages 766 - 778 |
MARIA L. KIREEVA ET AL.: "Cyr61, a Product of a Growth Factor-Inducible Immediate-Early Gene, Promotes Cell Proliferation, Migration, and Adhesion", MOLECULAR AND CELLULAR BIOLOGY, April 1996 (1996-04-01), pages 1326 - 1334 |
NATURE, vol. 432, no. 7014, 11 December 2003 (2003-12-11), pages 173 - 8 |
NUCLEIC ACID RES., vol. 31, 2003, pages 589 - 595 |
NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 4539 - 4557 |
NUCLEIC ACIDS RESEARCH, vol. 38, no. 17, 2010, pages 5761 - 5773 |
NUCLEIC ACIDS RESEARCH, vol. 39, no. 5, 2011, pages 1823 - 1832 |
P.J. BARNES; R.A. STOCKELY: "COPD: current therapeutic interventions and future approaches", EUR RESPIR J., vol. 25, 2005, pages 1084 - 1106 |
PAUWELS ET AL., AM J RESPIR CRIT CARE MED, vol. 163, 2001, pages 1256 - 1276 |
PETER J. CASTALDI ET AL.: "The COPD genetic association compendium", HUMAN MOLECULAR GENETICS, vol. 19, no. 3, 2010, pages 526 - 534 |
POLYMER SCI. TECHNOL., vol. 23, no. 3, pages 254 - 259 |
PROC. NATL. ACAD. SCI., vol. 93, no. 21, 15 December 1995 (1995-12-15), pages 11493 - 8 |
RNA, vol. 9, 2003, pages 1034 - 1048 |
See also references of EP3018209A4 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10829760B2 (en) | 2010-10-22 | 2020-11-10 | Olix Pharmaceuticals, Inc. | Nucleic acid molecules inducing RNA interference, and uses thereof |
US10883105B2 (en) | 2012-05-22 | 2021-01-05 | Olix Pharmaceuticals, Inc. | RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor |
US10590423B2 (en) | 2015-11-16 | 2020-03-17 | Olix Pharmaceuticals, Inc. | Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3 |
US10947541B2 (en) | 2016-02-02 | 2021-03-16 | Olix Pharmaceuticals, Inc. | Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1 |
WO2017178883A3 (en) * | 2016-04-11 | 2018-08-23 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor |
KR20180128423A (ko) * | 2016-04-11 | 2018-12-03 | 올릭스 주식회사 | 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법 |
US10301628B2 (en) | 2016-04-11 | 2019-05-28 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor |
US10829761B2 (en) | 2016-04-11 | 2020-11-10 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor |
KR102339886B1 (ko) | 2016-04-11 | 2021-12-17 | 올릭스 주식회사 | 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법 |
US11040057B2 (en) | 2016-06-29 | 2021-06-22 | Olix Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for potentiating gene silencing |
US11591600B2 (en) | 2017-02-10 | 2023-02-28 | OliX Pharmaceuticals. Inc. | Long double-stranded RNA for RNA interference |
EP4063504A4 (en) * | 2019-11-22 | 2024-03-06 | Bioneer Corp | CTGF GENE SPECIFIC DOUBLE STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION AND TREATMENT OF FIBROTIC DISEASES AND RESPIRATORY DISEASES COMPRISING THE SAME |
Also Published As
Publication number | Publication date |
---|---|
RU2016103695A (ru) | 2017-08-15 |
CN110592082A (zh) | 2019-12-20 |
EP3018209B1 (en) | 2019-10-16 |
BR112016000163A2 (pt) | 2017-11-28 |
EP3018209A4 (en) | 2017-06-07 |
RU2656154C2 (ru) | 2018-05-31 |
JP6677679B2 (ja) | 2020-04-08 |
MX2016000019A (es) | 2016-08-18 |
CN105683377A (zh) | 2016-06-15 |
JP2017225447A (ja) | 2017-12-28 |
CA2917320C (en) | 2020-10-13 |
CA2917320A1 (en) | 2015-01-08 |
CN105683377B (zh) | 2019-05-21 |
AU2014284836A1 (en) | 2016-02-18 |
CN110592083A (zh) | 2019-12-20 |
JP2020062023A (ja) | 2020-04-23 |
AU2014284836B2 (en) | 2017-07-27 |
EP3018209A2 (en) | 2016-05-11 |
US20160122764A1 (en) | 2016-05-05 |
JP6899509B2 (ja) | 2021-07-07 |
JP2016525346A (ja) | 2016-08-25 |
EP3591053A1 (en) | 2020-01-08 |
KR20160033125A (ko) | 2016-03-25 |
WO2015002513A3 (ko) | 2015-03-05 |
KR101867414B1 (ko) | 2018-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015002513A2 (ko) | 호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물 | |
WO2015152693A2 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
WO2019156365A1 (ko) | 엔도좀 탈출능을 갖는 펩티드 핵산 복합체 및 이의 용도 | |
WO2018030789A1 (ko) | 세포투과성이 향상된 펩티드 핵산 복합체 및 이를 포함하는 약학적 조성물 | |
WO2013089522A1 (ko) | 신규한 올리고뉴클레오티드 접합체 및 그 용도 | |
WO2019225968A1 (ko) | 엠피레귤린 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 | |
WO2015002511A1 (ko) | 개선된 고효율 나노입자형 올리고뉴클레오타이드 구조체 및 그의 제조방법 | |
WO2010090452A2 (ko) | 세포 내 전달능이 증가된 작은 간섭 rna 복합체 | |
WO2019156366A1 (ko) | 핵산 복합체를 함유하는 피부 투과성 전달체 및 이의 용도 | |
EP3472362A1 (en) | Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection | |
WO2017034344A1 (en) | Improved cell-permeable (icp)-socs3 recombinant protein and uses thereof | |
WO2013103249A1 (ko) | 고효율 나노입자형 이중나선 올리고 rna 구조체 및 그의 제조방법 | |
WO2014054927A1 (ko) | 엠피레귤린 특이적 이중 나선 올리고 rna, 그러한 이중나선 올리고 rna를 포함하는 이중나선 올리고 rna 구조체 및 이를 포함하는 호흡기 질환의 예방 또는 치료용 조성물 | |
WO2018110980A1 (ko) | B형 간염 예방 또는 치료용 의약 조성물 | |
WO2015002512A1 (ko) | 뎅기 바이러스 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 뎅기 바이러스 증식 억제용 조성물 | |
WO2019022586A9 (ko) | 간암의 예방 또는 치료용 약학적 조성물 | |
WO2015005669A1 (en) | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME | |
WO2019240503A1 (ko) | B형 간염 예방 또는 치료용 조성물 | |
WO2020149644A1 (ko) | Dkk1 유전자를 표적으로 하는 이중나선 올리고뉴클레오티드, 이를 포함하는 구조체 및 이를 포함하는 탈모 예방 또는 발모용 조성물 | |
WO2018026212A2 (ko) | 섬유증 질환 모델의 제조방법 및 섬유증 질환 모델의 용도 | |
WO2018220034A1 (en) | Antisense oligonucleotides for modulating htra1 expression | |
WO2021101113A1 (ko) | Ctgf 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 | |
WO2016204515A1 (ko) | STAT3 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체, 이를 포함하는 조성물 및 이의 용도 | |
WO2020096234A1 (ko) | 피부 투과성 핵산 복합체를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 조성물 | |
WO2022139528A1 (ko) | 만노스를 포함하는 지질 나노입자 또는 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14820458 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2917320 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016523670 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/000019 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016000163 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20167002234 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014820458 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016103695 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014284836 Country of ref document: AU Date of ref document: 20140704 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112016000163 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112016000163 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160105 |